Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$71 Mln
P/E Ratio
--
P/B Ratio
0.48
Industry P/E
--
Debt to Equity
--
ROE
-0.17 %
ROCE
-17.19 %
Div. Yield
0 %
Book Value
3.1
EPS
-0.52
CFO
$-241.47 Mln
EBITDA
$-287.47 Mln
Net Profit
$-271.44 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cassava Sciences (SAVA)
| -29.66 | -41.55 | -34.39 | -91.92 | -55.63 | -25.66 | -19.24 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cassava Sciences (SAVA)
| -89.32 | -23.80 | -32.40 | 540.76 | 31.15 | 511.76 | -78.57 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 9,808.03 | 20.22 | 23.13 | |
| 302.88 | 8,956.09 | 22.08 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational... diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas. Address: 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731 Read more
Founder, Chairman, President & CEO
Mr. Remi Barbier
CEO, President & Director
Mr. Richard Jon Barry
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cassava Sciences Inc (SAVA) stood at $ 158 Mln as on 31-Dec-24
The share price of Cassava Sciences Inc (SAVA) is $1.66 (NASDAQ) as of 24-Apr-2025 16:03 EDT. Cassava Sciences Inc (SAVA) has given a return of -55.63% in the last 3 years.
Cassava Sciences Inc (SAVA) has a market capitalisation of $ 71 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cassava Sciences Inc (SAVA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cassava Sciences Inc (SAVA) and enter the required number of quantities and click on buy to purchase the shares of Cassava Sciences Inc (SAVA).
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas. Address: 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
The CEO & director of Mr. Remi Barbier. is Cassava Sciences Inc (SAVA), and CFO & Sr. VP is Mr. Richard Jon Barry.
There is no promoter pledging in Cassava Sciences Inc (SAVA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Cassava Sciences Inc. (SAVA) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.19
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cassava Sciences Inc (SAVA) was $0 Mln.
